cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.5124613
title: Supplementary Material for: A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart Failure

description: <b><i>Aims:</i></b> To determine if newer criteria for diagnosing and staging acute kidney injury (AKI) during heart failure (HF) admission are more predictive of clinical outcomes at 30 days and 1 year than the traditional worsening renal function (WRF) definition. <b><i>Methods:</i></b> We analyzed prospectively collected clinical data on 637 HF admissions with 30-day and 1-year follow-up. The incidence, stages, and outcomes of AKI were determined using the following four definitions: KDIGO, RIFLE, AKIN, and WRF (serum creatinine rise ≥0.3 mg/dl). Receiver operating curves were used to compare the predictive ability of each AKI definition for the occurrence of adverse outcomes (death, rehospitalization, dialysis). <b><i>Results:</i></b> AKI by any definition occurred in 38.3% (244/637) of cases and was associated with an increased incidence of 30-day (32.3 vs. 6.9%, χ<sup>2</sup> = 70.1; p &lt; 0.001) and 1-year adverse outcomes (67.5 vs. 31.0%, χ<sup>2</sup> = 81.4; p &lt; 0.001). Most importantly, there was a stepwise increase in primary outcome with increasing stages of AKI severity using RIFLE, KDIGO, or AKIN (p &lt; 0.001). In direct comparison, there were only small differences in predictive abilities between RIFLE and KDIGO and WRF concerning clinical outcomes at 30 days (AUC 0.76 and 0.74 vs. 0.72, χ<sup>2</sup> = 5.6; p = 0.02) as well as for KDIGO and WRF at 1 year (AUC 0.67 vs. 0.65, χ<sup>2</sup> = 4.8; p = 0.03). <b><i>Conclusion:</i></b> During admission for HF, the benefits of using newer AKI classification systems (RIFLE, AKIN, KDIGO) lie with the ability to identify those patients with more severe degrees of AKI who will go on to experience adverse events at 30 days and 1 year. The differences in terms of predictive abilities were only marginal.
DOI: 10.6084/m9.figshare.5124616
title: Supplementary Material for: Psychologische Flexibilität messen: Der Fragebogen zu Akzeptanz und Handeln II

description: Medicine
DOI: 10.6084/m9.figshare.5124601
title: Supplementary Material for: The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme

description: Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10% of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50% inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM.
DOI: 10.6084/m9.figshare.5124607
title: Supplementary Material for: Plasma Cell Neoplasms Showing Multilobulated Nuclei

description: Medicine
DOI: 10.6084/m9.figshare.5124604
title: Supplementary Material for: Steroid Withdrawal in Pediatric Kidney Transplant Allows Better Growth, Lipids and Body Composition: A Randomized Controlled Trial

description: <b><i>Background:</i></b> Glucocorticoid immunosuppressant therapy in pediatric kidney transplant (Tx) recipients does not allow the improvement of growth after Tx. <b><i>Objective:</i></b> To determine the effect of early steroid withdrawal (SW) on longitudinal growth, insulin sensitivity (IS), and body composition (BC). <b><i>Methods:</i></b> This was a prospective, randomized, multicenter study in Tx. Insulin-like growth factor (IGF)-I, IGF-binding protein 3 (IGFBP3), IS, and BC (DEXA/pQCT) were determined at baseline and up to 12 months after Tx. <b><i>Results:</i></b> A total of 30 patients were examined; 14 patients were assigned to the SW group (7 male, 7 female; 12 in Tanner stage I) and 16 patients were assigned to the steroid control (SC) group (10 male, 6 female;12 in Tanner stage I). Their chronological age was 7.8 ± 4.3 years, height was -2.3 ± 0.99 SD scores (SDS), and body mass index -0.3 ± 1.2 SDS. After 1 year, the SW group showed an increase in height SDS (+1.2 ± 0.22 vs. +0.60 ± 0.13 SDS in the SC group, p &lt; 0.02), lower IGFBP3 (p &lt; 0.05), cholesterol (p &lt; 0.05), and higher high-density lipoprotein cholesterol (p &lt; 0.05). SW patients had lower trunk fat with no differences in IS. Only in prepubertal patients, the SW group had lower glycemia (p &lt; 0.05), very low-density lipoprotein cholesterol (p &lt; 0.01), triglycerides (p &lt; 0.05), triglycerides/glycemia index (TyG; p &lt; 0.02), and better lean mass. Both groups showed an improvement in lean mass after kidney Tx. <b><i>Conclusions:</i></b> SW improved longitudinal growth, lipid profile, and trunk and lean fat in Tx patients. In prepubertal recipients, the decrease in TyG suggests better IS.
DOI: 10.6084/m9.figshare.5124607.v1
title: Supplementary Material for: Plasma Cell Neoplasms Showing Multilobulated Nuclei

description: Medicine
DOI: 10.6084/m9.figshare.5124601.v1
title: Supplementary Material for: The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme

description: Glioblastoma multiforme (GBM) is one of the most common and aggressive types of primary brain tumor. After complete surgical resection combined with radiation and chemotherapy, approximately 10% of patients survive for more than 5 years. Therefore, a novel therapy for GBM is needed. Aurora-A (AURKA) plays important roles in cell cycle regulation, such as centrosome maturation, chromatic separation, bipolar spindle assembly, and mitotic entry. To investigate the effects of AURKA inhibition, three GBM cell lines, including GBM 8401, GBM 8901, and U87-MG cells, were treated with the AURKA inhibitor VE-465. Sensitivities to VE-465, as indicated by 50% inhibitory concentration values for GBM 8401, GBM 8901, and U87-MG cells, were 6, 25, and 19 nM, respectively. Additionally, colony formation of GBM 8401 and GBM 8901 cells was decreased after treatment with the VE-465. VE-465 treatment increased polyploidy and p53 protein expression, and inhibited cell growth in a caspase-independent manner. Taken together, these results suggest that the inhibition of AURKA by a small-molecule inhibitor may have potential to serve as a novel therapeutic approach for GBM.
DOI: 10.6084/m9.figshare.5124598
title: Supplementary Material for: Botulinum Toxin in the Treatment of Lingual Dystonia Induced by Speaking

description: Primary lingual dystonia is a rare condition, especially when it is only induced by speaking. Trihexyphenidyl failed to improve the symptoms. Several case series have demonstrated the effectiveness of botulinum toxin injection for the management of focal lingual movement disorders. Only 1 case of botulinum toxin injection for primary lingual dystonia induced by speaking has been reported, but this treatment has limited effectiveness. Our patient was treated with botulinum toxin using a superficial approach for injection into the tongue with continuing excellent results. Lingual botulinum toxin injection is a fairly simple, safe and viable treatment option for lingual dystonia induced by speaking.
DOI: 10.6084/m9.figshare.5124604.v1
title: Supplementary Material for: Steroid Withdrawal in Pediatric Kidney Transplant Allows Better Growth, Lipids and Body Composition: A Randomized Controlled Trial

description: <b><i>Background:</i></b> Glucocorticoid immunosuppressant therapy in pediatric kidney transplant (Tx) recipients does not allow the improvement of growth after Tx. <b><i>Objective:</i></b> To determine the effect of early steroid withdrawal (SW) on longitudinal growth, insulin sensitivity (IS), and body composition (BC). <b><i>Methods:</i></b> This was a prospective, randomized, multicenter study in Tx. Insulin-like growth factor (IGF)-I, IGF-binding protein 3 (IGFBP3), IS, and BC (DEXA/pQCT) were determined at baseline and up to 12 months after Tx. <b><i>Results:</i></b> A total of 30 patients were examined; 14 patients were assigned to the SW group (7 male, 7 female; 12 in Tanner stage I) and 16 patients were assigned to the steroid control (SC) group (10 male, 6 female;12 in Tanner stage I). Their chronological age was 7.8 ± 4.3 years, height was -2.3 ± 0.99 SD scores (SDS), and body mass index -0.3 ± 1.2 SDS. After 1 year, the SW group showed an increase in height SDS (+1.2 ± 0.22 vs. +0.60 ± 0.13 SDS in the SC group, p &lt; 0.02), lower IGFBP3 (p &lt; 0.05), cholesterol (p &lt; 0.05), and higher high-density lipoprotein cholesterol (p &lt; 0.05). SW patients had lower trunk fat with no differences in IS. Only in prepubertal patients, the SW group had lower glycemia (p &lt; 0.05), very low-density lipoprotein cholesterol (p &lt; 0.01), triglycerides (p &lt; 0.05), triglycerides/glycemia index (TyG; p &lt; 0.02), and better lean mass. Both groups showed an improvement in lean mass after kidney Tx. <b><i>Conclusions:</i></b> SW improved longitudinal growth, lipid profile, and trunk and lean fat in Tx patients. In prepubertal recipients, the decrease in TyG suggests better IS.
DOI: 10.6084/m9.figshare.5124589
title: Supplementary Material for: Colony-Stimulating Factor-1-Responsive Macrophage Precursors Reside in the Amphibian <b><i>(Xenopus laevis)</i></b> Bone Marrow rather than the Hematopoietic Subcapsular Liver

description: Macrophage precursors originate from and undergo lineage commitment within designated sites of hematopoiesis, such as the mammalian bone marrow. These cells subsequently differentiate in response to stimulation with macrophage colony-stimulating factor-1 (CSF-1). The amphibian bone marrow, unlike that of mammals, has been overlooked as a source of leukocyte precursors in favor of the liver subcapsular region, where hematopoiesis occurs in anurans. Here we report that the bone marrow rather than the liver periphery provides macrophage progenitors to the amphibian <i>Xenopus laevis</i>. We identified the amphibian CSF-1, examined its gene expression in developing and virally infected <i>X. lae</i><i> vis</i> and produced it in recombinant form (r<i>Xl</i>CSF-1). This r<i>Xl</i>CSF-1 did not bind or elicit proliferation/differentiation of subcapsular liver cells. Surprisingly, a subpopulation of bone marrow cells engaged this growth factor and formed r<i>Xl</i>CSF-1 concentration-dependent colonies in semisolid medium. Furthermore, r<i>Xl</i>CSF-1-treated bone marrow (but not liver) cultures comprised of cells with characteristic macrophage morphology and high gene expression of the macrophage marker CSF-1 receptor. Together, our findings indicate that in contrast to all other vertebrates studied to date, committed <i>Xenopus </i>macrophage precursor populations are not present at the central site of hematopoiesis, but reside in the bone marrow.
DOI: 10.6084/m9.figshare.5124592
title: Supplementary Material for: Narrowband Ultraviolet B Interferes with Gene Expression in the Peripheral Blood T Cells of Patients with Psoriasis

description: <b><i>Background:</i></b> Psoriasis pathogenesis and development are closely related to abnormal T cell activity. Narrowband ultraviolet B (NB-UVB) treatment markedly improves skin lesions in psoriasis. <b><i>Objectives:</i></b> To investigate differential gene expression in psoriasis and to understand the possible mechanisms of NB-UVB therapy for psoriasis. <b><i>Methods:</i></b> The mRNA expression profiles and differentially expressed genes from peripheral blood T cells of psoriatic patients before and after NB-UVB treatment were examined using RNA sequencing and validated by real-time reverse-transcription polymerase chain reaction. <b><i>Results:</i></b> A total of 129 genes were differentially expressed in the peripheral blood T cells of psoriatic patients: 83 genes were downregulated and 46 were upregulated in psoriatic patients compared to those of healthy subjects. These genes were enriched in intracellular membrane-bound organelles, membrane-bound organelles and the nucleus, and are involved in the cell cycle, apoptosis, inflammation and other processes. These changes are reversed in psoriatic patients with good clinical outcomes following NB-UVB treatment. <b><i>Conclusion:</i></b> NB-UVB treatment has beneficial effects on local psoriatic lesions, possibly due to its effect on peripheral blood T cell gene expression.
DOI: 10.6084/m9.figshare.5124595
title: Supplementary Material for: Systematic Review on Daily Vitamin B12 Losses and Bioavailability for Deriving Recommendations on Vitamin B12 Intake with the Factorial Approach

description: <b><i>Aims:</i></b> To systematically review the literature on daily losses and bioavailability of vitamin B12. These estimates could be used for deriving recommendations on vitamin B12 intake for adults and elderly. <b><i>Methods:</i></b> We identified publications on daily vitamin B12 losses (July 2011) and publications on the bioavailability of vitamin B12 from foods or diets (June 2010) in MEDLINE, EMBASE and the Cochrane Library. <b><i>Results:</i></b> A pooled analysis of five studies (52 subjects) showed that 0.13 ± 0.03% of the total body store is lost per day. Absorption of vitamin B12 ranged from 4.5 (dose of 38 µg from consumption of liver) to 83% (dose of 3.0 µg from consumption of mutton meat). Data from eight studies including 83 subjects suggested that the amount of vitamin B12 absorbed from food (A<sub>i</sub>) increased with increasing doses of vitamin B12 (D<sub>i</sub>) as described by the equation: ln(A<sub>i</sub>) = 0.7694 * ln(D<sub>i</sub>) - 0.9614. <b><i>Conclusion:</i></b> Daily vitamin B12 losses in apparently healthy adults and elderly probably range from 1.4 to 5.1 µg. Vitamin B12 intakes needed to compensate for these losses seem to range from 3.8 to 20.7 µg. More evidence is needed on the relationships between biochemical markers of vitamin B12 status, vitamin B12 body store and long-term health outcomes to evaluate whether current recommendations on vitamin B12 intake (1.4-3 µg) need to be changed.
DOI: 10.6084/m9.figshare.5124586
title: Supplementary Material for: O-Methylated Metabolite of 7,8-Dihydroxyflavone Activates TrkB Receptor and Displays Antidepressant Activity

description: 7,8-Dihydroxyflavone (7,8-DHF) acts as a TrkB receptor-specific agonist. It mimics the physiological actions of brain-derived neurotrophic factor (BDNF) and demonstrates remarkable therapeutic efficacy in animal models of various neurological diseases. Nonetheless, its in vivo pharmacokinetic profiles and metabolism remain unclear. Here we report that 7,8-DHF and its O-methylated metabolites distribute in mouse brain after oral administration. Both hydroxy groups can be mono-methylated, and the mono-methylated metabolites activate TrkB in vitro and in vivo. Blocking methylation, using COMT inhibitors, diminishes the agonistic effect of TrkB activation by 7,8-DHF or 4′-dimethylamino-7,8-DHF, supporting the contribution of the methylated metabolite to TrkB activation in mouse brain. Moreover, we have synthesized several methylated metabolite derivatives, and they also potently activate the TrkB receptor and reduce immobility in both forced swim test and tail suspension test, indicating that these methylated metabolites may possess antidepressant activity. Hence, our data demonstrate that 7,8-DHF is orally bioavailable and can penetrate the brain-blood barrier. The O-methylated metabolites are implicated in TrkB receptor activation in the brain.
DOI: 10.6084/m9.figshare.5124598.v1
title: Supplementary Material for: Botulinum Toxin in the Treatment of Lingual Dystonia Induced by Speaking

description: Primary lingual dystonia is a rare condition, especially when it is only induced by speaking. Trihexyphenidyl failed to improve the symptoms. Several case series have demonstrated the effectiveness of botulinum toxin injection for the management of focal lingual movement disorders. Only 1 case of botulinum toxin injection for primary lingual dystonia induced by speaking has been reported, but this treatment has limited effectiveness. Our patient was treated with botulinum toxin using a superficial approach for injection into the tongue with continuing excellent results. Lingual botulinum toxin injection is a fairly simple, safe and viable treatment option for lingual dystonia induced by speaking.
DOI: 10.6084/m9.figshare.5124583
title: Supplementary Material for: Adult Serum Cytokine Concentrations and the Persistence of Asthma

description: <b><i>Background:</i></b> Cytokines play a pivotal role in regulating the development and persistence of the inflammatory process in asthma. Our aim was to investigate whether asthma persistence or remission is associated with a specific cytokine profile. <b><i>Methods:</i></b> The Tasmanian Longitudinal Health Study followed participants from 7 to 44 years of age. Serum concentrations of interleukin (IL)-4, IL-5, IL-6, IL-8, IL-10 and tumor necrosis factor-alpha (TNF-α) were measured at age 44 years. Participants were categorized into five phenotypes (early-onset noncurrent asthma, early-onset current asthma, late-onset noncurrent asthma and late-onset current asthma). Those who had never had asthma formed the reference group. Multivariable linear regression was used to compare serum cytokine concentrations between each phenotype and the reference group. <b><i>Results:</i></b> IL-10 concentrations were significantly lower in serum from the early-onset current asthma group than in the reference group (ratio of geometric means 0.58; 95% confidence interval 0.33-0.99; p = 0.048). IL-6 concentrations for the late-onset remitted group were also significantly lower than in the reference group (p = 0.009). The TNF-α concentrations were significantly lower for both early-and late-onset remitted asthma phenotypes when compared with the reference group. No associations were detected between serum concentrations of IL-4, IL-5 or IL-8 and these specific longitudinal asthma phenotypes. <b><i>Conclusion:</i></b> Our findings suggest a possible role for deficient IL-10 responses in the persistence of early-onset asthma. Lower IL-6 and TNF-α concentrations in serum from those with remitted asthma suggest that these proinflammatory cytokines may be actively suppressed during asthma remission.
DOI: 10.6084/m9.figshare.5124589.v1
title: Supplementary Material for: Colony-Stimulating Factor-1-Responsive Macrophage Precursors Reside in the Amphibian <b><i>(Xenopus laevis)</i></b> Bone Marrow rather than the Hematopoietic Subcapsular Liver

description: Macrophage precursors originate from and undergo lineage commitment within designated sites of hematopoiesis, such as the mammalian bone marrow. These cells subsequently differentiate in response to stimulation with macrophage colony-stimulating factor-1 (CSF-1). The amphibian bone marrow, unlike that of mammals, has been overlooked as a source of leukocyte precursors in favor of the liver subcapsular region, where hematopoiesis occurs in anurans. Here we report that the bone marrow rather than the liver periphery provides macrophage progenitors to the amphibian <i>Xenopus laevis</i>. We identified the amphibian CSF-1, examined its gene expression in developing and virally infected <i>X. lae</i><i> vis</i> and produced it in recombinant form (r<i>Xl</i>CSF-1). This r<i>Xl</i>CSF-1 did not bind or elicit proliferation/differentiation of subcapsular liver cells. Surprisingly, a subpopulation of bone marrow cells engaged this growth factor and formed r<i>Xl</i>CSF-1 concentration-dependent colonies in semisolid medium. Furthermore, r<i>Xl</i>CSF-1-treated bone marrow (but not liver) cultures comprised of cells with characteristic macrophage morphology and high gene expression of the macrophage marker CSF-1 receptor. Together, our findings indicate that in contrast to all other vertebrates studied to date, committed <i>Xenopus </i>macrophage precursor populations are not present at the central site of hematopoiesis, but reside in the bone marrow.
DOI: 10.6084/m9.figshare.5124577
title: Supplementary Material for: Vitamin D Treatment and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis

description: <b><i>Background/Aims:</i></b> Hypovitaminosis D has been associated with an increased cardiovascular mortality in the general population and in patients with chronic kidney disease (CKD). Still, whether prescribing vitamin D reduces the risk of mortality in renal patients remains controversial. <b><i>Methods:</i></b> We searched PubMed, ClinicalTrials.gov and the Cochrane Library for long-term longitudinal studies comparing vitamin D compounds (25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and synthetic derivatives) to placebo or no treatment in renal patients, and which evaluated mortality, to perform a meta-analysis. Data concerning study quality, population and effect size were extracted independently by two investigators using predefined forms. <b><i>Results:</i></b> Fourteen observational studies (194,932 patients) met all eligibility criteria. Most studies were performed in hemodialysis patients and all used calcitriol or synthetic analogues. In a random effects meta-analysis, receiving any vitamin D therapy significantly reduced the risk of all-cause mortality (relative risk 0.73, 95% CI 0.65-0.82). The relative risk of death was 0.72 (95% CI 0.65-0.80) after 3 years of therapy and 0.67 (95% CI 0.45-0.98) after 5 years. In meta-regression, the risk reduction was shown to be greater in patients with higher parathyroid hormone serum levels (p = 0.01). The risk of cardiovascular mortality was also significantly reduced in patients receiving any vitamin D derivative (relative risk 0.63, 95% CI 0.44-0.92). <b><i>Conclusion:</i></b> Therapies with 1,25-dihydroxyvitamin D and analogues are associated with reduced mortality in CKD patients, and particularly in those suffering from secondary hyperparathyroidism. These results, based on observational evidence, are supportive of prescribing vitamin D therapies to CKD patients, while respecting good practice guidelines.